WWA
CRSP icon

WCG Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

WCG Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$544K Buy
11,436
+499
+5% +$26.3K 0.02% 448
2025
Q4 		$574K Buy
+10,937
New +$655K 0.02% 432

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCG Wealth Advisors's CRSP Position: Q1 2026 in Review

WCG Wealth Advisors increased its CRISPR Therapeutics (CRSP) stake by 4.6% in Q1 2026, buying an estimated $26.3K and bringing the position to 11,436 shares worth $544K. The position accounts for 0.02% of the portfolio, ranked #448.

WCG Wealth Advisors first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. The position peaked at $574K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • WCG Wealth Advisors held 11,436 shares of CRISPR Therapeutics worth $544K as of Q1 2026.
  • WCG Wealth Advisors bought 499 CRISPR Therapeutics shares in Q1 2026, an estimated $26.3K.
  • CRISPR Therapeutics made up 0.02% of WCG Wealth Advisors's portfolio in Q1 2026, its #448 holding.
  • WCG Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • WCG Wealth Advisors's CRISPR Therapeutics position peaked at $574K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on WCG Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.